



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/00 (2006.01)

C12Q 1/6886 (2018.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2021/044688

(22) International Filing Date:

05 August 2021 (05.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/061,507 05 August 2020 (05.08.2020) US

(71) Applicant: **DRAGONFLY THERAPEUTICS, INC.**
[US/US]; 35 Gatehouse Drive, Waltham, MA 02451 (US).(72) Inventors: **GRINBERG, Asya**; 37 Follen Road, Lexington, MA 02421 (US). **JUO, Zong, Sean**; F8-1, No. 129, Xingyun Street, Neihu District, Taipei, 114 (TW). **LIHARSKA, Katia**; 567 Middlesex Turnpike, Billerica, MA 01821 (US). **MORGAN, Christopher, Ryan**; 25 Marlboro Rd, Southborough, MA 01772 (US).(74) Agent: **ASHRAF, Shovon** et al.; Goodwin Procter LLP, 100 Northern Avenue, 10th Docketing Dept/7th Fl, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIBODIES TARGETING EGFR AND USE THEREOF




FIG. 11

(57) Abstract: Disclosed are proteins with antibody heavy chain and light chain variable domains that can be paired to form an antigen-binding site targeting EGFR on a cell, pharmaceutical compositions comprising such proteins, and therapeutic methods using such proteins and pharmaceutical compositions, including for the treatment of cancer.

